Could nonprofit drug companies cut sky-high prices?

May 17, 2018 by Amy Norton, Healthday Reporter

(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Earlier this year, the consortium of several large hospital systems announced it would form a nonprofit drug called Project Rx.

The goal, its members said, is to address two major problems in the current generic drug market: shortages of critical drugs and inflated prices.

The man spearheading the is Dan Liljenquist of Intermountain Healthcare, a large network of hospitals and clinics in Utah. Together with several other systems—and in collaboration with the U.S. Department of Veterans Affairs and philanthropists—Intermountain plans to get Project Rx running by next year.

Writing in the May 17 New England Journal of Medicine, Liljenquist and his colleagues help present the argument for why it just might work.

It's not the first time the idea of a nonprofit drug company has been floated, said Ge Bai, an assistant professor at Johns Hopkins Business School in Baltimore.

But those proposals never panned out, said Bai, co-author of the journal article. (Johns Hopkins' medical institutions are not part of the group launching Project Rx.)

The principle behind Project Rx gives it a better shot at success, however, Bai said.

The customers in this case are the hospitals, and each will have a direct contract with the nonprofit drug maker, Bai explained. Hospitals know how much of a given drug they need, and the drug manufacturer will be guaranteed a minimum volume of sales—at a predetermined low price.

But Project Rx—or, eventually, other nonprofits—could also have broader effects. They could help drive down generic drug prices by introducing competition into markets where there currently is none, Bai explained.

The problem is, when it comes to without a large customer base—for uncommon medical conditions, for instance—there is often only one company making the medication.

Increasingly, companies are buying up monopolies on old, off-patent drugs. Then they have the power to dictate the price.

Possibly the most famous case involved the anti-parasite drug Daraprim, which has a market of only about 6,000 patients in the United States, according to the report. In 2015, the pharmaceutical company Turing bought the rights for the drug, then promptly raised the price by more than 5,000 percent—from $13.50 a pill to $750.

Another example in the report is a drug called Syprine. It has been used since the 1960s to treat Wilson's disease, a rare condition that causes copper to accumulate in the organs. After the company Valeant acquired rights to make the drug in 2010, it raised the monthly price from $652 to nearly $21,300.

In addition, U.S. hospitals have been facing shortages of critical drugs. This can easily happen when only one or two manufacturers make a medication.

To actually make its drugs, Project Rx will contract with an existing manufacturer, Bai said. And its initial focus, she added, will be on selling hospitals generic injectable drugs that are in short supply and high-priced.

It's a feasible plan, said Jack Hoadley, a researcher at Georgetown University's Health Policy Institute in Washington, D.C.

Lack of competition is the problem with certain generic drugs, said Hoadley, who is not connected to the project.

"So if a nonprofit essentially creates competition," he said, "one of the expectations is that for-profit companies will lower their prices."

What about getting cheaper generics to not only hospitals, but patients?

That's the ultimate goal, Bai said.

The logistics would be more complicated, she noted. The company would have to contract with a "middle man," such as pharmacy benefit managers or wholesalers, to get the medications to individuals.

Hoadley agreed that plan sounds reasonable.

But even if one or more nonprofits gets off the ground, they will not be the sole answer to skyrocketing prescription , Hoadley noted. "This wouldn't address the issue of highly expensive drugs with patent protection," he said.

But, Hoadley added, "this could eventually make a big difference for certain patients. Off-patent drugs should be cheap."

Explore further: Hospital groups creating company to make cheap generic drugs

More information: Ge Bai, Ph.D., C.P.A., assistant professor, accounting, Johns Hopkins Carey Business School, Baltimore; Jack Hoadley, Ph.D., health policy analyst, Center for Medicare and Medicaid Research, Health Policy Institute, Georgetown University, Washington, D.C.; May 17, 2018, New England Journal of Medicine, Abstract/Full Text

The U.S. Food and Drug Administration has more on generic prescription drugs.

Related Stories

Hospital groups creating company to make cheap generic drugs

January 18, 2018
Several major not-for-profit hospital groups are trying their own solution to drug shortages and high medicine prices: creating a company to make cheaper generic drugs.

Hospitals hit back on drug pricing, but will they knock out the problem?

March 28, 2018
Drug manufacturing and pricing vaulted into the news several years ago when a privately held company raised the price of a drug used for infections from US$13.50 to $750 for one pill.

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

FDA takes steps to boost generic competition, limit prices

June 27, 2017
The Food and Drug Administration is taking steps to boost the number of generic prescription drugs in an effort to make medicines more affordable and to prevent price gouging.

As competition goes down, generic drug prices rise, study finds

July 3, 2017
If the cost of your generic prescription drug has risen, it may be due to a lack of competition among drug manufacturers, according to a University of Florida College of Pharmacy study.

Recommended for you

US approves first generic competitor to Mylan's EpiPen

August 16, 2018
US regulators Thursday approved the first generic alternative for the EpiPen, a life-saving emergency allergy medicine, two years after soaring prices for the original version owned by Mylan stoked controversy.

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.